Facebook
X
LinkedIn
ForwardTransplanting Hope: The Intersection of Liver Transplantation and Alcohol Use Disorder - March 20, 2026
In-Person and Virtual attendance options are available.
Explore the evolving landscape of managing patients with alcohol use disorder who require liver transplantation in our comprehensive course. Tailored for physicians, healthcare providers, and social workers, this program delves into the changing paradigm of care, highlighting innovative therapies and the integration of emotional intelligence to foster collaborative, effective teams. Gain insights into the latest research and treatment strategies that address alcohol use disorder, ensuring a holistic approach to improving patient outcomes and enhancing the overall quality of care for this complex population. Join us as we equip you with the knowledge and tools needed to navigate this critical intersection of addiction treatment and liver transplantation.
FEES
| REGISTRATION TYPE | FEE |
|---|---|
| Houston Methodist Employee | $25 |
| Physician (Private physician located within the Greater Houston Area)* | $230 |
| Physician (Private physician located outside the Greater Houston Area) | $75 |
| External Allied Health Care Professional (Non-Houston Methodist) | $50 |
| Resident / Fellow / Student | Complimentary |
* In compliance with HM’s policy on Physician Non-Monetary Compensation regarding “Stark Law,” private physicians who reside and/or practice medicine within the Greater Houston Area are required to pay the full Fair Market Value registration fee.
Presenters, topics, program schedule, and credit is subject to change
Target Audience
This program is designed for hepatologists, gastroenterologists, transplant surgeons, addiction medicine specialists, psychiatrists, psychologists, internists, primary care physicians, social workers, nurses, and allied health professionals involved in the care of patients with liver disease, alcohol use disorder, and transplantation. It will also benefit those with an interest in ethical decision-making, multidisciplinary transplant management, and integrated approaches to addiction treatment.
Learning Objectives
- Describe the pathophysiological mechanisms by which alcohol contributes to the development and progression of fatty liver disease, including its impact on lipid metabolism and inflammation.
- Explain the role of the intestinal microbiome in the etiology and maintenance of alcohol addiction, including how dysbiosis may influence gut-liver axis interactions and addiction pathways.
- Identify evidence-based criteria for selecting patients with alcohol use disorder as candidates for liver transplantation, including psychosocial, medical, and ethical considerations.
- Recognize key risk factors and characteristics associated with relapse in patients who have undergone liver transplantation for alcohol use disorder, such as behavioral patterns, genetic predispositions, and post-transplant support needs.
- Evaluate the overall impact of alcohol use disorder on liver transplantation outcomes and discuss strategies for multidisciplinary management, including prevention, monitoring, and integration of the program's key topics into clinical practice.
- Evaluate emerging evidence on the role of GLP-1 agonists in the treatment of alcohol addiction, including their mechanisms of action, potential therapeutic applications, and implications for patients with alcohol use disorder undergoing liver transplantation.
- Recognize the role of liver transplantation in acute alcoholic hepatitis and the medical/surgical and psychosocial evaluation that is required for optimal outcome and survival.
| Transplanting Hope: The Intersection of Liver Transplantation and Alcohol Use Disorder (AUD) | ||
| AGENDA │ Friday, March 20, 2026 | ||
| Time | Topics | Speaker |
| 7:00 AM | Registration and Breakfast | |
| 7:45 AM | Welcome and Introduction | Joseph Galati, MD |
| Plenary Session I: Moderators: Caroline Simon, MD and Kavish Paditar, MD | ||
| 8:00 AM | 3 Questions: Emotional Intelligence And Managing A Transplant Program | Chuck Garcia CEO, Climb Leadership International |
| 8:20 AM | 3 Questions: Managing Individuals With AUD And Addiction | George Joseph CEO, Common Bond and Positive Recovery |
| 8:35 AM | 3 Questions: Acute Alcoholic Hepatitis And Liver Transplantation | Gene Im, MD, FAASLD Transplant Hepatologist Director, Alcohol-Associated Liver Disease Program Columbia Presbytarian Hospital |
| 8:55 AM | Q&A Discussion (10 min) | |
| Pleanary Session II: Moderator: Ashish Saharia, MD and Hana Nguyen, NP | ||
| 9:05 AM | 3 Questions: Managing A Transplant Medical Review Board | John Ontiveros, LCSW-S HMH |
| 9:20 AM | 3 Questions: Effects Of Alcohol On Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | David Victor, MD HMH |
| 9:35 AM | 3 Questions: Intestinal Microbiome And Addiction | Eamonn Quigley, MD HMH |
| 9:50 AM | Q&A Discussion (10 min) | |
| 10:00AM | Morning Break (15 min) | |
| Session 3 Moderator: Michelle Jones-Pauley, MD and John Ontiveros, LCSW-S | ||
| 10:15 AM | 3 Questions: Strategies To Reduce Alcohol Relapse After Transplant | Gerald Scott Winder, MD, MSc, FACLP, Henry Ford Health |
| 10:35 AM | 3 Questions: Out-Patient Management Of AUD Post Transplant | Kerry Ewens, LCSW-S HMH |
| 10:50 AM | 3 Questions: Role Of Alcohol And Liver Cancer | Sudah Kodhali, MD HMH |
| 11:10 AM | 3 Questions: Absolute Contraindication To Liver Transplant | Kavish Patidar, MD HMH |
| 11:30 AM | Q&A and Discussion (20 min) | |
| 11:50 AM | Lunch | |
| Session 4 Moderator: David Victor, MD and Natalie Amante, PA | ||
| 1:00 PM | 3 Questions: Why Is There Reluctance To Drop The 6-Month Rule | Victor Ankoma-Sey, MD HMH |
| 1:15 PM | 3 Questions: Medical Management Of AUD | Akhil Shenoy, MD Psychiatrist, Columbia Presbytarian Hospital |
| 1:36 PM | 3 Questions: Role Of GLP-1 Agents In Addiction | Archana Sadhu, MD HMH |
| 1:50 PM | 3 Questions: Houston Methodist Experience | Ashton Connor, MD HMH |
| 2:05 PM | Q&A amd Discussion (15 min) | |
| Session 5 Moderator: Constance Mobley, MD and Andrea Duchini, MD | ||
| 2:15 PM | 3 Questions: Outpatient Community Based Treatment Of AUD | Kevin Johnson, LCDC Positive Recovery Center |
| 2:30 PM | 3 Questions: Heart Transplant And AUD | Ash Guha, MD HMH |
| 2:45 PM | 3 Questions: Kidney Transplant And AUD | Peter Nguyen, MD HMH |
| 3:00 PM | Q&A | |
| 3:15 PM | Afternoon Break | |
| Session 6 Moderator: Joseph Galati, MD | ||
| 3:30 PM | Lighting Rounds: Tying It All Together With Case Studies | Gene Im, MD |
| Scott Wilder, MD | ||
| Chuck Garcia | ||
| Akil Shenoy, MD | ||
| Mark Ghobrial MD | ||
| John Ontiveros, LCSW-S | ||
| 4:15 PM | Closing Remarks | Joseph Galati, MD Mark Ghobrial, MD |
| 4:20 PM | Adjourn | |
In-Person attendance will be held in the Houston Methodist Research Institute (6670 Bertner Avenue, Houston, Texas 77030).
Virtual information will be provided to registered learners.
Available Credit
- 6.50 AMA PRA Category 1 Credit™
Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Houston Methodist designates this Live activity for a maximum of 6.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 6.50 Attendance
Price
FEES
FEES
| REGISTRATION TYPE | FEE |
|---|---|
| Houston Methodist Employee | $25 |
| Physician (Private physician located within the Greater Houston Area)* | $230 |
| Physician (Private physician located outside the Greater Houston Area) | $75 |
| External Allied Health Care Professional (Non-Houston Methodist) | $50 |
| Resident / Fellow / Student | Complimentary |
* In compliance with HM’s policy on Physician Non-Monetary Compensation regarding “Stark Law,” private physicians who reside and/or practice medicine within the Greater Houston Area are required to pay the full Fair Market Value registration fee.
Presenters, topics, program schedule, and credit is subject to change